{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T05:09:58Z","timestamp":1740460198742,"version":"3.37.3"},"reference-count":15,"publisher":"European Respiratory Society (ERS)","issue":"2","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2022,3,29]]},"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Pulmonary endarterectomy (PEA) is recommended for eligible patients with chronic thromboembolic pulmonary hypertension (CTEPH) and is potentially curative. However, persistent\/recurrent CTEPH post-PEA can occur. Here we describe symptom and diagnostic assessment rates for residual disease post-PEA and longitudinal diagnostic patterns before and after riociguat approval for persistent\/recurrent CTEPH after PEA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This US retrospective cohort study analysed MarketScan data (1 January 2002\u201330 September 2018) from patients who underwent PEA following a CTEPH\/pulmonary hypertension (PH) claim with at least 730\u2005days of continuous enrolment post-PEA. Data on pre-specified PH symptoms and the types and timings of diagnostic assessments were collected.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 103 patients (pre-riociguat approval, n=55; post-riociguat approval, n=48), residual PH symptoms &gt;3\u2005months after PEA were reported in 89% of patients. Overall, 89% of patients underwent one or more diagnostic tests (mean 4.6 tests\/patient), most commonly echocardiography (84%), with only 5% of patients undergoing right heart catheterisation (RHC). In the post-<jats:italic>versus<\/jats:italic>pre-riociguat approval subgroup, assessments were more specific for CTEPH with an approximately two-fold increase in 6-min walk distance and<jats:italic>N<\/jats:italic>-terminal prohormone of brain natriuretic protein measurements and ventilation\/perfusion scans, and a four-fold increase in RHCs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Low RHC rates suggest that many patients with PH symptoms post-PEA are not being referred for full diagnostic workup. Changes to longitudinal diagnostic patterns may indicate increased recognition of persistent\/recurrent CTEPH post-PEA; however, there remains a need for greater awareness around the importance of continued follow-up for patients with residual PH symptoms post-PEA.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00572-2021","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T16:22:09Z","timestamp":1653322929000},"page":"00572-2021","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment for residual disease after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension"],"prefix":"10.1183","volume":"8","author":[{"given":"Ois\u00edn","family":"Butler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1011-4434","authenticated-orcid":false,"given":"Shinyoung","family":"Ju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soeren","family":"Hoernig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Vogtl\u00e4nder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameer","family":"Bansilal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9797-2599","authenticated-orcid":false,"given":"Gustavo A.","family":"Heresi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"2024101711341399000_8.2.00572-2021.1","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01032-2015"},{"key":"2024101711341399000_8.2.00572-2021.2","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0112-2016"},{"key":"2024101711341399000_8.2.00572-2021.3","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S2213-2600(14)70089-X","article-title":"Chronic thromboembolic pulmonary hypertension","volume":"2","author":"Hoeper","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2024101711341399000_8.2.00572-2021.4","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01915-2018"},{"key":"2024101711341399000_8.2.00572-2021.5","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.015008"},{"key":"2024101711341399000_8.2.00572-2021.6","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.016522"},{"key":"2024101711341399000_8.2.00572-2021.7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.115.019470"},{"key":"2024101711341399000_8.2.00572-2021.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2010.11.024"},{"key":"2024101711341399000_8.2.00572-2021.9","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0111-2016"},{"key":"2024101711341399000_8.2.00572-2021.10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.tcm.2016.05.010","article-title":"Update on chronic thromboembolic pulmonary hypertension","volume":"27","author":"Robbins","year":"2017","journal-title":"Trends Cardiovasc Med"},{"key":"2024101711341399000_8.2.00572-2021.11","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/j.amjmed.2016.03.006","article-title":"Monitoring for pulmonary hypertension following pulmonary embolism: the INFORM study","volume":"129","author":"Tapson","year":"2016","journal-title":"Am J Med"},{"key":"2024101711341399000_8.2.00572-2021.12","unstructured":"Bayer AG . ADEMPAS (riociguat) tablets, for oral use. Highlights of prescribing information. www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/204819s011lbl.pdf Date last accessed: 8 September 2019."},{"key":"2024101711341399000_8.2.00572-2021.13","doi-asserted-by":"crossref","first-page":"2045894020961713","DOI":"10.1177\/2045894020961713","article-title":"Evaluation of code-based algorithms to identify pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension patients in large administrative databases","volume":"10","author":"Sprecher","year":"2020","journal-title":"Pulm Circ"},{"key":"2024101711341399000_8.2.00572-2021.14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-publhealth-040617-013544"},{"key":"2024101711341399000_8.2.00572-2021.15","doi-asserted-by":"publisher","DOI":"10.1111\/1475-6773.12008"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00572-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:18:57Z","timestamp":1740374337000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00572-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,5,30]]},"published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1183\/23120541.00572-2021"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00572-2021","relation":{},"ISSN":["2312-0541"],"issn-type":[{"type":"electronic","value":"2312-0541"}],"subject":[],"published":{"date-parts":[[2022,4]]}}}